{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:04:39Z","timestamp":1774418679361,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10147-026-02977-5","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:52:53Z","timestamp":1769849573000},"page":"658-665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4790-7529","authenticated-orcid":false,"given":"Yuri","family":"Takamatsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8935-0768","authenticated-orcid":false,"given":"Yoshiya","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8535-4008","authenticated-orcid":false,"given":"Yasuo","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9226-895X","authenticated-orcid":false,"given":"Junichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4557-5126","authenticated-orcid":false,"given":"Goro","family":"Kutomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"2977_CR1","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.2217\/fon-2017-0283","volume":"13","author":"O Garrone","year":"2017","unstructured":"Garrone O, Miraglio E, Vandone AM et al (2017) Eribulin in advanced breast cancer: safety, efficacy and new perspectives. Future Oncol 13:2759\u20132769","journal-title":"Future Oncol"},{"key":"2977_CR2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D et al (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914\u2013923","journal-title":"Lancet"},{"key":"2977_CR3","doi-asserted-by":"publisher","first-page":"102715","DOI":"10.1016\/j.eclinm.2024.102715","volume":"74","author":"M Takahashi","year":"2024","unstructured":"Takahashi M, Kikawa Y, Kashiwabara K et al (2024) Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial. EClinicalMedicine 74:102715","journal-title":"EClinicalMedicine"},{"key":"2977_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/bjc.2015.183","volume":"113","author":"CH Koh","year":"2015","unstructured":"Koh CH, Bhoo-Pathy N, Ng KL et al (2015) Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer 113:150\u2013158","journal-title":"Br J Cancer"},{"key":"2977_CR5","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1038\/bjc.2014.163","volume":"110","author":"S Krenn-Pilko","year":"2014","unstructured":"Krenn-Pilko S, Langsenlehner U, Thurner EM et al (2014) The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer 110:2524\u20132530","journal-title":"Br J Cancer"},{"key":"2977_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10549-022-06748-4","volume":"196","author":"H Jimbo","year":"2022","unstructured":"Jimbo H, Horimoto Y, Ishizuka Y et al (2022) Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer. Breast Cancer Res Treat 196:291\u2013298","journal-title":"Breast Cancer Res Treat"},{"key":"2977_CR7","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s12282-020-01069-0","volume":"27","author":"M Myojin","year":"2020","unstructured":"Myojin M, Horimoto Y, Ito M et al (2020) Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer. Breast Cancer 27:732\u2013738","journal-title":"Breast Cancer"},{"key":"2977_CR8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12282-020-01067-2","volume":"27","author":"Y Miyoshi","year":"2020","unstructured":"Miyoshi Y, Yoshimura Y, Saito K et al (2020) High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician\u2019s choice-in the EMBRACE study. Breast Cancer 27:706\u2013715","journal-title":"Breast Cancer"},{"key":"2977_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10549-020-05626-1","volume":"181","author":"J Watanabe","year":"2020","unstructured":"Watanabe J, Saito M, Horimoto Y et al (2020) A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience. Breast Cancer Res Treat 181:211\u2013220","journal-title":"Breast Cancer Res Treat"},{"key":"2977_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403\u2013410","journal-title":"Histopathology"},{"key":"2977_CR11","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1245\/s10434-015-4934-0","volume":"23","author":"Y Asano","year":"2016","unstructured":"Asano Y, Kashiwagi S, Onoda N et al (2016) Predictive value of neutrophil\/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol 23:1104\u20131110","journal-title":"Ann Surg Oncol"},{"key":"2977_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.21873\/cdp.10058","volume":"1","author":"Y Koyama","year":"2021","unstructured":"Koyama Y, Kawai S, Uenaka N et al (2021) Absolute lymphocyte count, platelet-to-lymphocyte ratio, and overall survival in eribulin-treated HER2-negative metastatic breast cancer patients. Cancer Diagn Progn 1:435\u2013441","journal-title":"Cancer Diagn Progn"},{"key":"2977_CR13","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.21873\/anticanres.15095","volume":"41","author":"S Nakamoto","year":"2021","unstructured":"Nakamoto S, Ikeda M, Kubo S et al (2021) Dynamic changes in absolute lymphocyte counts during eribulin therapy are associated with survival benefit. Anticancer Res 41:3109\u20133119","journal-title":"Anticancer Res"},{"key":"2977_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12885-024-11923-5","volume":"24","author":"MX Su","year":"2024","unstructured":"Su MX, Lin HW, Nguyen HTH et al (2024) Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin. BMC Cancer 24:195","journal-title":"BMC Cancer"},{"key":"2977_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C et al (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33:594\u2013601","journal-title":"J Clin Oncol"},{"key":"2977_CR16","doi-asserted-by":"publisher","first-page":"7010","DOI":"10.1038\/s41598-020-63291-2","volume":"10","author":"L Gerratana","year":"2020","unstructured":"Gerratana L, Basile D, Toffoletto B et al (2020) Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. Sci Rep 10:7010","journal-title":"Sci Rep"},{"key":"2977_CR17","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi Y, Okamoto K, Adachi Y et al (2014) Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 105:1334\u20131342","journal-title":"Cancer Sci"},{"key":"2977_CR18","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/cas.13392","volume":"108","author":"K Ito","year":"2017","unstructured":"Ito K, Hamamichi S, Abe T et al (2017) Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models. Cancer Sci 108:2273\u20132280","journal-title":"Cancer Sci"},{"key":"2977_CR19","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/bjc.2016.122","volume":"114","author":"S Ueda","year":"2016","unstructured":"Ueda S, Saeki T, Takeuchi H et al (2016) In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br J Cancer 114:1212\u20131218","journal-title":"Br J Cancer"},{"key":"2977_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74\u201380","journal-title":"Science"},{"key":"2977_CR21","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1038\/bcj.2017.60","volume":"7","author":"T Dosani","year":"2017","unstructured":"Dosani T, Covut F, Beck R et al. Significance of the absolute lymphocyte\/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma. Blood Cancer J 7:e579","journal-title":"Blood Cancer J"},{"key":"2977_CR22","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21217","author":"B Zhao","year":"2017","unstructured":"Zhao B, Zhao H (2017) Incidence and risk of eribulin mesylate related hematologic toxicity. Oncotarget 8: 93813-93824","journal-title":"Oncotarget"},{"key":"2977_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12282-018-0843-y","volume":"25","author":"S Ohtani","year":"2018","unstructured":"Ohtani S, Nakayama T, Yoshinami T et al (2018) Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY). Breast Cancer 25:438\u2013446","journal-title":"Breast Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02977-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-02977-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02977-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:13:08Z","timestamp":1774415588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-02977-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2977"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-02977-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Junichiro Watanabe (JW) is a Reviewer Board member of the International Journal of Clinical Oncology and a coauthor of this article. To minimize bias, he was excluded from all editorial decision-making related to the acceptance of this article for publication. Yasuo Miyoshi (YM) and JW have received lecture fees from Eisai. All other authors declare no relevant financial or non-financial conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Juntendo University Hospital (H16-0096-H01) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"An opt-out approach was used with the disclosure of website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}